N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 23.5 CNY -6.67% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Nanjing Vazyme Biotech Co Ltd?
Write Note

Nanjing Vazyme Biotech Co Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanjing Vazyme Biotech Co Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Common Stock
ÂĄ400m
CAGR 3-Years
4%
CAGR 5-Years
93%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Common Stock
ÂĄ906k
CAGR 3-Years
4%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Common Stock
ÂĄ1.3B
CAGR 3-Years
43%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Common Stock
ÂĄ6.6B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
27%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Common Stock
ÂĄ2.4B
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
12%
Imeik Technology Development Co Ltd
SZSE:300896
Common Stock
ÂĄ216.4m
CAGR 3-Years
22%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Nanjing Vazyme Biotech Co Ltd
Glance View

Market Cap
9.3B CNY
Industry
Biotechnology

Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. The company is headquartered in Nanjing, Jiangsu and currently employs 1,409 full-time employees. The company went IPO on 2021-11-15. The firm's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The firm's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.

Intrinsic Value
23.45 CNY
Fairly Valued
Intrinsic Value
Price
N

See Also

What is Nanjing Vazyme Biotech Co Ltd's Common Stock?
Common Stock
400m CNY

Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Common Stock amounts to 400m CNY.

What is Nanjing Vazyme Biotech Co Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
93%

Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Nanjing Vazyme Biotech Co Ltd have been 4% over the past three years , 93% over the past five years .

Back to Top